

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

VOLUNTARY ANNOUNCEMENT NMPA APPROVAL FOR REGISTRATION OF BIOHEART® BIOABSORBABLE DRUG-ELUTING STENTS

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on June 29, 2029, Bioheart® bioabsorbable drug-eluting stents (“**BRS**”) developed by the Company, has been approved by the National Medical Products Administration of the People’s Republic of China (國家藥品監督管理局) (“**NMPA**”), for the patients with ischemic heart disease caused by native coronary lesions, to improve the intracoronary lumen diameter. Detailed results of the pivotal trial for the Bioheart® BRS have been published in *JACC: Cardiovascular Interventions* (Vol. 18, No. 1, 2025).

ABOUT Bioheart® BRS

Bioheart®, our self-developed bioresorbable scaffold (BRS) system, is designed for percutaneous coronary intervention (PCI) in the treatment of coronary artery disease. Engineered to be fully resorbed by the human body over time, Bioheart® temporarily maintains vessel patency, effectively reducing elastic recoil and acute occlusion while preventing restenosis. The anti-proliferative drug eluted from the scaffold inhibits neointimal hyperplasia, serving a purpose equivalent to that of a drug-eluting stent (DES). As the vessel heals and the need for mechanical radial support diminishes, the scaffold gradually resorbs. Consequently, Bioheart® achieves true anatomical and functional “vascular restoration” rather than leaving a permanent artificial foreign body. Once fully absorbed, no residual foreign material remains

in the vessel, perfectly embodying the clinical philosophy of “leaving nothing behind” and “intervention without implantation”.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that Bioheart® BRS will be ultimately developed and marketed successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive director

Shanghai, the People’s Republic of China, July 2, 2026

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.